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Abstract
Background: Epigenetic events mediated by methylation and histone modifications have been associated with the
development of metastasis in patients with uveal melanoma. The role of epigenetic events mediated by microRNA
(miR) is less clear. Tumor and plasma miR expression was examined in patients with primary uveal melanoma with
tumor monosomy-3, a predictor of metastasis.
Results: miR profiling of tumors by microarray found six miRs over-expressed and 19 under-expressed in 33 tumors
with monosomy-3 compared to 22 without. None of the miRs differentially expressed in tumors with and without
monosomy-3 was differentially expressed in tumors with and without tumor infiltrating lymphocytes. Tumors
manifesting monosomy-3 were also characterized by higher levels of TARBP2 and DDX17 and by lower levels of
XPO5 and HIWI, miR biogenesis factors. miR profiling of plasma by a quantitative nuclease protection assay found
elevated levels of 11 miRs and reduction in four in patients with tumor monosomy-3. Only three miRs differentially
expressed in the tumor arrays were detectable in plasma. miRs implicated in uveal melanoma development were
not differentially expressed. Elevated plasma levels in patients with tumor monosomy-3 of miR-92b, identified
in the tumor array, and of miR-199-5p and miR-223, identified in the plasma array, were confirmed by
quantitative real-time polymerase chain reaction. Levels were also higher in patients compared to normal
controls.
Conclusions: These results support a role for epigenetic mechanisms in the development of metastasis in
patients with uveal melanoma and the analysis of miRs as biomarkers of metastatic risk. They also suggest
that potentially useful blood miRs may be derived from the host response as well as the tumor.
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Background
Uveal melanoma is a rare cancer that leads to metastatic
death in up to half of patients. That loss of chromosome
3 in tumors is associated with the development of
metastasis is well established, and a variety of techniques
are being used to test tumors for monosomy-3 [1]. Gene
expression profiling (GEP) has also been effectively
applied to characterize tumors with a high risk of metas-
tasis, “class 2,” and tumors with a low risk, “class 1” [2].
Epigenetic events have also been implicated in uveal
melanoma metastasis. When independently analyzed for
global DNA methylation profiles, primary uveal melano-
mas cluster into two groups that are identical to the class-
2 and class-1 groups identified by GEP [3]. Expression
levels of a number of histone-modifying genes and
polycomb family members are significantly lower in uveal
melanoma with monosomy-3/class-2 GEP [4]. Although
epigenetic events mediated by microRNA (miR) have been
implicated in uveal melanoma development [5–7], a role
for miRs in the metastatic process has not been estab-
lished. Worley et al. found six miRs to be upregulated
in 12 tumors expressing high-risk, class-2 GEP and
68 to be upregulated in 12 tumors expressing low-
risk, class-1 GEP [8]. The most significant discrimi-
nators of class 2 were upregulation of let-7b and
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miR-199a. In contrast, Larsen et al. found no association
between miR-expression profiles and histopathological
features, staging, metastasis, or survival in a study of 20
patients [9].
Obtaining uveal melanoma tumors for genotyping can
be problematic. There is a need for blood biomarkers
[10]. miRs are very stable in blood due in part to their
incorporation into microparticles and exosomes, and
serum and plasma levels of miRs are also under investi-
gation as diagnostic and prognostic biomarkers in cancer
and other diseases [11]. Blood miR levels have not been
previously reported in uveal melanoma. We used tumor
monosomy-3 as well as tumor and plasma miR profiling
as guides as to develop miR-based prognostic blood
biomarkers for patients with primary uveal melanoma.
We also examined the expression of miR biogenesis fac-




miR and gene expression profiles of 33 enucleated uveal
tumors with monosomy-3 and 22 without were obtained.
This analysis identified 26 miRs as discriminators; 19 were
down-regulated >2.0-fold and six were upregulated >2.0-
fold (Table 1). In this data set, 13 patients, all with tumor
monosomy-3, had manifested metastatic disease clinically
on follow-up. Eight of the 26 miRs identified were also
Table 1 Tumor miRs differentially expressed











Over-expressed in tumors with monosomy-3
hsa-miR-135a* 3 80 0.0003 NS ND ND
hsa-miR-624 14 7.6 0.0003 0.0004 ND ND
hsa-miR-449b 5 5.9 0.0005 NS ND ND
hsa-miR-142-5p 17 7.5 0.0006 NS 1236 1059
hsa-miR-92b 1 2.9 0.0009 NS 688 ND
hsa-miR-628-5p 15 4.8 0.001 NS ND ND
Under-expressed in tumors with monosomy-3
hsa-miR-509-3-5p X 615 0.00000008 0.0002 ND ND
hsa-miR-508-3p X 4672 0.0000003 0.0004 ND ND
hsa-miR-514 X 2887 0.0000009 NS ND ND
hsa-miR-506 X 1308 0.000001 0.0008 ND ND
hsa-miR-513a-5p X 1674 0.000002 0.001 ND ND
hsa-miR-507 X 61 0.000003 NS ND ND
hsa-miR-509-3p X 818 0.000004 0.0008 ND ND
hsa-miR-513b X 75 0.00003 0.00002 ND ND
hsa-miR-876-3p 9 81 0.00003 NS ND ND
hsa-miR-378* 5 5.1 0.0002 NS ND ND
hsa-miR-935 19 4.1 0.0003 0.001 ND ND
hsa-miR-181a 9 7.4 0.0004 NS 546 ND
hsa-miR-99a 21 5.6 0.0009 NS ND ND
hsa-miR-194 1 4.5 0.001 NS ND ND
hsa-miR-592 7 4.1 0.001 NS ND ND
hsa-miR-1296 10 15 0.001 NS ND ND
hsa-miR-624* 14 7.5 0.002 NS ND ND
hsa-miR-140-5p 16 10 0.002 NS ND ND
hsa-miR-651 X 6.1 0.002 NS ND ND
NS not significant, ND not detectable
aMonosomy-3, n = 33; disomy-3, n = 22
bMetastatic, n = 13; nonmetastatic, n = 42
cAverage signal intensity
Triozzi et al. Clinical Epigenetics  (2016) 8:80 Page 2 of 8
differentially expressed in these patients (Table 1). The
strongest associations with monosomy-3 were observed
for under-expression of X-linked miRs. Neither X-linked
miRs nor other any miRs were differentially expressed by
tumors from the 31 males compared to the 24 females
studied. Twenty-seven of the tumors evaluated were
considered to have TILs, a potential source of miRs; 28
were not. None of the miRs differentially expressed in
tumors with and without monosomy-3 was differentially
expressed in tumors with and without TILs. Gene expres-
sion of 12 miR biogenesis factors were also profiled by
microarray in the 55 enucleated uveal melanoma tumors.
Tumors manifesting monosomy-3 were characterized by
higher levels of TARB2 and DDX17 and lower levels of
XPO5 and HIWI (Fig. 1).
Plasma array
Plasma miR profiles of pooled samples from 10 patients
with monosomy-3 and 10 without were analyzed using
quantitative nuclease protection assay (qNPA). Of the
674 human miRs assayed, 96 were detectable in plasma.
Compared to patients without, 11 miRs were elevated
>2.0-fold and four were reduced >2.0-fold in patients
with tumor monosomy-3 (Table 2). None of the miRs
that was discriminatory in the tumor array met the level
of discrimination set for the plasma array. Only two of
the miRs over-expressed in the tumor array were quanti-
fiable in plasma, miR-92b and miR-142-5p (Table 1).
The 1.6-fold increase in plasma miR-92b was statistically
significant (P <0.02); the 1.2-fold increase in plasma miR-
142-5p was not (P <0.5). The only other miR measurable
in blood was miR-181a, levels of which were increased in
plasma while being under-expressed in tumors in the
presence of tumor monosomy-3.
Plasma miR quantification
Plasma levels of select miRs increased in the tumor and in
the pooled plasma arrays in the presence of tumor
monosomy-3 were then examined by quantitative real-time
polymerase chain reaction (qRT-PCR) in the individual
patients tested, again 10 with tumor monosomy-3 and 10
without. The focus was on the two miRs that were over-
expressed in the tumor array that were measurable in
plasma, miR-92b and miR-142-5p, and three miRs elevated
in the plasma array, miR-191, miR-199a-5p, and miR-223.
Three miRs previously reported to be upregulated in uveal
melanoma tumors compared to normal choroid, miR-20a,
miR-21, and miR-106a, that were not differentially
expressed in either the tumor or plasma array, were also
assessed [5]. Differential expression in plasma as assessed
by qRT-PCR paralleled the qNPA results (Fig. 2). miR-92b,
miR-199a-5p, and miR-223 were significant higher in both
the qNPA and the qRT-PCR analysis. miR-191 tended to be
higher in the qRT-PCR analysis, but increases did not reach
the level of significance (P < 0.10), as it did in the qNPA
analysis. miR-142-5, miR-20a, miR-21, and miR-106a were
not differentially expressed. Levels of the three miRs that
were significantly different were then examined in another
set of patients with primary uveal melanoma in which
tumor chromosome 3 status was obtained on fine needle
aspiration (FNA) biopsies. Levels of these miRs were also
compared to those of 26 healthy donor controls. Plasma
levels of miR-92b, 199a-5p, and 223 were significantly
higher in patients with monosomy-3 when compared to pa-
tients with disomy; levels of all three were also higher when
compared to levels of normal controls (Fig. 3).
Discussion
Tumor and plasma miR profiling of patients with pri-
mary uveal melanoma was applied to investigate the role
of epigenetic mechanisms in the metastatic process with
an overall goal to develop blood biomarkers that could
potentially help guide adjuvant therapy decisions and
follow-up. Of 858 miRs assessed in tumors manifesting
monosomy-3, an accurate predictor of the development
of metastasis, 6 were found to be over-expressed and 20,
under-expressed. The over-expressed miRs associated
with monosomy-3 were analyzed by DIANA mirPath
(Multiple microRNA Analysis), a web-based miR path-
way analysis application [12]. The top three pathways
potentially regulated were actin cytoskeleton, adherens
junctions, and TGF-beta signaling, pathways implicated
in metastasis, including in uveal melanoma [13–15]. Of
Table 2 Plasma miRs differentially expressed
miR Chr Monosomy-3a Disomy-3b P
Increased in patients with tumor monosomy-3
hsa-miR-191 3 7456 1760 0.0000001
hsa-miR-93 7 3344 836 0.000001
hsa-miR-221 X 10411 3449 0.00006
hsa-miR-342-3p 14 962 ND 0.00007
hsa-miR-19b 13 2385 1017 0.0002
hsa-miR-199a-5p 19 1977 ND 0.0003
hsa-miR-25 7 1490 ND 0.0009
hsa-miR-27a 19 5182 1993 0.0009
hsa-miR-23a 19 4566 1886 0.001
hsa-miR-15b 3 1195 530 0.001
hsa-miR-223 X 10286 3413 0.002
Decreased in patients with tumor monosomy-3
hsa-miR-1227 19 1686 10791 0.0000008
hsa-miR-663 20 2196 16206 0.00001
hsa-miR-654-5p 14 420 1148 0.00008
hsa-miR-1238 19 1561 6172 0.0001
aAverage signal intensity, n = 10
bAverage signal intensity, n = 10
ND not detectable
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note, whereas the target genes of most miRs are
enriched, for example, on chromosomes 6, 16, 17, 19,
and 22, miR target genes are not enriched on chromo-
some 3 [16]. None of the miRs we found to be differen-
tially expressed in tumors with monosomy-3 was
differentially expressed in tumors studied by Worley et
al. [8], who used the class-2 GEP as a surrogate for me-
tastasis. The most significant discriminators in our study
were under-expression of miRs of the 506-514 cluster,
which has been implicated in initiating melanocyte
transformation and promoting melanoma growth and
invasiveness [17, 18].
miR production is a complicated process requiring a
large number of molecular events to be coordinated.
None of the major miR biogenesis factors are encoded
on chromosome 3. Tumors manifesting monosomy-3
were characterized by alterations in miR processing fac-
tors, which have been associated with the development
of metastasis in several types of cancer. DDX17 and
TARBP2 were upregulated, and XPO5 and HIWI were
down-regulated. DDX17 (22q13.1), a nuclear endonucle-
ase that produces 60 to 70 nucleotide pre-miRs, was
identified as a metastasis-associated gene in renal cell
carcinoma [19]. A decrease in exportin 5 (XPO5;
6p21.1), which transports pre-miRs into the cytoplasm,
has been associated with prognosis in head and neck
and in lung cancers [20, 21]. Upregulation of TARBP2
(12q12-q13), a cytoplasmic endonuclease which cleaves
pre-miRs into 21 to 22 nucleotide mature miRs in con-
junction with Dicer (DICER1), has been associated with
metastasis in breast cancer [22]. Down regulation of
HIWI (12q24.33), which is integrated into the silencing
complex, has been associated with metastasis in pancre-
atic cancer [23]. Alterations in Dicer, Drosha, and Gemin4,
which have been observed in cutaneous melanoma, were
not observed [24]. Most of the miRs identified that were
discriminatory in tumors with monosomy-3 were down-
regulated. How the alterations in miR biogenesis factors
influenced this observation will require further study.
None of the miRs that we found to be discriminatory
in the tumor array was found to be discriminatory in the
plasma array. The plasma miRs most significantly
increased was miR-191, which has been implicated in
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Fig. 2 Plasma miR quantification by qRT-PCR in patients with enucleated tumors with (M), n = 10, and without (D), n = 10, tumor monosomy-3.
The box represents the 25th and 75th percentiles, the horizontal lines represent the median, and the whiskers represent the minimum and maximum.
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Fig. 1 miR biogenesis factor expression by gene expression array in enucleated tumors with (M), n = 33, and without (D), n = 22, monosomy-3.
The box represents the 25th and 75th percentiles, the horizontal lines represent the median, and the whiskers represent the minimum and maximum.
Brackets with an asterisk above indicate statistical significance P <0.05 , **P < 0.01, Wilcoxon rank-sum test
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confirm using qRT-PCR that specific miRs differentially
expressed in the arrays were increased in the plasma of
patients with tumor monosomy-3 and significantly in-
creased when compared to levels in normal donors.
These included one miR over-expressed in the tumor
array, miR-92b, and two increased in the plasma array,
miR-199a-5p and miR-223. These miRs have also been
implicated in several cellular processes. All three have
been implicated in regulating genes that promote metas-
tasis [26–28]. All three also regulate host responses. Of
note, miR-92b belongs to a cluster of miRs that regulate
T cells, including regulatory T cells [29], miR-199a-5p
promotes regulatory T cells [30], and miR-223 regulates
myeloid suppressor cells [31]. Regulatory T cells and
myeloid suppressor cells have been implicated in uveal
melanoma progression [32, 33]. Plasma levels of miRs
reported to be upregulated in uveal melanoma tumors
when compared to normal choroid, miR-20a, miR-21,
and miR-106a, were also measured to examine the
possibility that increases may represent circulating
uveal melanoma cells, a potential predictor of metas-
tasis [5, 34]. Levels of these miRs were not increased
in the plasma of patients with tumor monosomy-3.
Virtually, all of the miRs discriminatory in the tumor
array were not quantifiable in the plasma array. In contrast
to tumor where more miRs were differentially under-
expressed, more miRs were differentially increased in the
plasma in patients with tumor monosomy-3 compared to
without. That miR-expression patterns of tumor differ
from those of blood has been previously reported [35].
Several mechanisms may generate blood miRs, including
passive leakage from apoptotic or necrotic cells and active
secretion of miR-containing microparticles and exosomes.
These can occur in malignant cells but also in
nonmalignant cells with a short half-life, such as blood
cells, or upon tissue damage. There is evidence that most
circulating miRs are blood-cell derived [36]. At least 100
different miRs have been shown to circulate in the blood
of healthy donors, including most of the miRs we found to
be differentially increased, miR-19b, miR-191, miR-199a-
5p, miR-25, miR-23a, miR-223, and miR-93 [37, 38].
Several of the differentially expressed miRs identified have
been previously reported to be elevated in the plasma or
serum of patients with cancer, including miR-92b in
prostate [39]; miR-223 in lung, esophageal, and hepatocel-
lular [40–42]; and miRs-199a-5p, miRs-19b, miRs-15b, and
miRs-25 in lung [40, 43, 44].
In addition to chromosome 3, abnormalities in
chromosomes 1, 6, and 8 have also been associated with
metastasis in uveal melanoma. Only three of the 26
tumor miRs and two of the 18 plasma miRs differentially
expressed are located on these chromosomes. One of
the miRs over-expressed in the tumor array, miR-135a*,
localizes to chromosome 3. miR levels are regulated
by several transcriptional and post transcription me-
chanisms as well as poorly understood degradation
pathways [45]. miR-135a levels are regulated by Wnt/
beta-catenin signaling [46]. Wnt/beta-catenin signaling
has been implicated in uveal melanoma development
[47]. The miR-506-514 cluster maps to the human X
chromosome, which contains approximately 10 % of all
miRs detected in the human genome. miR-223 and miR-
221, which were increased in plasma, are also X-linked.
Although the role of most has not yet been described,
several X-linked miRs have been shown to have import-
ant functions in cancer as well as in immunity [48].
Nonrandom abnormalities have been previously ob-
















Fig. 3 Plasma miR quantification by qRT-PCR in patients with (M), n = 33, and without (D), n = 32, monosomy-3 in which tumor chromosome 3
status was obtained on FNA biopsies. Also displayed are plasma levels of normal controls (N), n = 26. The box represents the 25th and 75th
percentiles, the horizontal lines represent the median, and the whiskers represent the minimum and maximum. Brackets with an asterisk above
indicate statistical significance P < 0.05, **P < 0.01, Kruskal-Wallis test
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a consensus regarding their prognostic significance has
not been established [49–51]. Although males manifest a
slightly higher incidence and mortality rate, gender is
not considered to play a major role in uveal melanoma
predisposition or prognosis [52].
Conclusions
These results, which derive from the largest number of
uveal melanoma samples reported to date, support a role
for epigenetic events mediated by miRs in uveal melan-
oma metastasis and further analysis of miRs as biomarkers
of metastatic risk. They also suggest that potentially useful
blood miRs may be derived from the host response as well
as the tumor. Tumor monosomy-3 and class-2 GEP,
although accurate predictors, are surrogate endpoints of
metastatic death. Larger scale, prospective studies with
clinical endpoints, including early compared to late metas-
tases, will be necessary. The use of blood miR levels in
conjunction with imaging studies as part of systemic
surveillance for metastasis also merits study.
Methods
Patients
Tumors that had been cryopreserved from patients with
uveal melanoma treated by enucleation at the Cleveland
Clinic Cole Eye Institute between 2004 and 2010 were
analyzed. Starting in 2009, blood was also collected from
patients treated with enucleation and from patients under-
going FNA biopsy at the time of plaque radiotherapy.
Computed tomography scans of the chest, abdomen, and
pelvis were initially performed to rule out metastatic dis-
ease. Chromosome 3 status in the enucleation specimen
was assessed by single nucleotide polymorphism array and
in the FNA biopsies by fluorescent in situ hybridization as
previously described [53]. Standard clinical and histologic
characteristics were also assessed. This included the pres-
ence or absence of significant TILs, which was defined as
being more than 100 lymphocytes in 20 high power (40×)
fields [54]. All patients underwent scheduled surveillance
for the development of metastases with clinical evaluation
with liver imaging.
Tumor miR array
Total RNA was extracted from 25 mg of cryopreserved
tumor tissue using Trizol Reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions and
further purified using the miRNeasy Mini Kit (Qiagen,
Valencia, CA). RNA quality was assessed using the
Agilent 2100 Bioanalyzer, and concentration was mea-
sured using Nanodrop 1000 (Thermo Fisher Scientific,
Waltham, MA). The total RNA (400 ng) was hybridized
to the Illumina MicroRNA Profiling BeadChip, contain-
ing 858 mature human miR probes and 287 hypothetical
small RNA probes according to the standard protocol.
Tumor miR biogenesis factors
RNA was isolated from snap-frozen primary uveal
melanoma tissue isolated from enucleated eyes. Purity
and concentration were determined using a NanoDrop
ND-1000 Spectrometer. Quality RNA was subsequently
hybridized using a direct hybridization array kit
(Illumina). Each RNA sample was hybridized using the
HumanHT-12 BeadChip array (Illumina) in a multiple-
step procedure; the chips were washed, dried, and
scanned on the BeadArray Reader (Illumina). Raw
microarray data were generated using BeadStudio v3.0
(Illumina). Microarray data analysis and quality control
were performed using BeadArray R package v1.0.0. After
background subtraction (using median background
method), the data were normalized using quantile
normalization and log-transformed.
Plasma miR array
Plasma samples were forwarded to the HTG Molecular
Diagnostics, Inc. (Tucson, AZ) for miR profiling using
qNPA. The expression of 674 human miRs was analyzed
using Whole Transcript miRNA Microarray Version 11.
Each sample was tested in duplicate.
Plasma miR quantification
The total RNA was isolated from plasma using the miR-
Neasy Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. With the exceptions of miR-
142-5p and miR-92b, reverse transcription reactions
were performed using a TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions. qRT-PCR
was performed using the reverse transcription reaction
product, TaqMan MicroRNA Assay kit, and TaqMan
Universal PCR Master Mix (Applied Biosystems) accord-
ing to the manufacturer’s instructions. TaqMan Micro-
RNA Assay kits for human miRs were used. Reactions
were loaded onto a 96-well plate and run in duplicate on
an ABI 7500 Fast Real-Time PCR System (Applied Biosys-
tems). The reactions were incubated at 50 °C for 20 s and
95 °C for 10 min, followed by 40 cycles of denaturation at
95 °C for 15 s, then 1 min of annealing/extension at 60 °C.
The ΔΔCT method was used to determine relative
number of copies (RQ) of miR. Data were normalized to a
Caenorhabditis elegans synthetic miR sequence, cel-miR-
39 (Qiagen), which was spiked in as a control during RNA
isolation. The miScript PCR System from Qiagen
(Valencia, CA) was used for quantification of miR-142-5p
and miR-92b. miRs were isolated as described previously;
5 μL of isolated template RNA were used for subsequent
reverse transcription reactions which were performed
using the miScript II RT Kit according to the manufac-
turer’s instructions. Real-time PCR was performed using
2× QuantiTect SYBR Green PCR Master Mix, 10×
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miScript Universal Primer, 10× miScript Primer Assay,
and template cDNA from reverse transcription; all
reaction volumes suggested by the manufacturer were
doubled to perform reactions in duplicate.
Statistical analysis
Significance analysis of microarrays (http://statweb.-
stanford.edu/~tibs/SAM/) was used to identify miRs
differentially expressed between monosomy- and disomy-
3 tumors. Normalization by median centering and t test
statistic were used in the analysis. In order not to miss
subtly expressed miRs in tumors that may be measureable
in plasma, the false discovery rate threshold for the tumor
array was set at <0.01. Expression of tumor miR biogenesis
factors was evaluated by Wilcoxon rank-sum tests. The
miR array of plasma from patients with monosomy- and
disomy-3 was analyzed by HTG Molecular Diagnostics,
Inc. Data were normalized to the total signal for each
microarray. Results are reported as average signal inten-
sities. miRs were considered quantifiable if the average sig-
nal intensity was >526 in plasma from monosomy-3 donors
and >531 in plasma from disomy-3 donors. Differentially
expressed plasma miRs were selected using random vari-
ance t test, P <0.05, and absolute fold change >2.0. Differen-
tial expression of plasma RQ of specific miRs was assessed
by Wilcoxon rank-sum test for comparison between two
groups or Kruskal-Wallis test for comparison between
multiple groups. All tests were two-sided with P < 0.05
considered significant.
Abbreviations
FNA, fine needle aspiration; GEP, gene expression profiling; miR, microRNA;
qNPA, quantitative nuclease protection assay; qRT-PCR, quantitative real-time
polymerase chain reaction; RQ, relative number of copies
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